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We conducted a multicentre test-negative case–con-
trol study in 27 hospitals of 11 European countries to 
measure 2015/16 influenza vaccine effectiveness (IVE) 
against hospitalised influenza A(H1N1)pdm09 and B 
among people aged ≥ 65 years. Patients swabbed within 
7 days after onset of symptoms compatible with severe 
acute respiratory infection were included. Information 
on demographics, vaccination and underlying con-
ditions was collected. Using logistic regression, we 
measured IVE adjusted for potential confounders. We 
included 355 influenza A(H1N1)pdm09 cases, 110 influ-
enza B cases, and 1,274 controls. Adjusted IVE against 
influenza A(H1N1)pdm09 was 42% (95% confidence 
interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 
48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% 
(95%  CI: 7 to 60) in patients with diabetes mellitus, 
cancer, lung and heart disease, respectively. Adjusted 
IVE against influenza B was 52% (95%  CI: 24 to 70). 
It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) 
and 36% (95% CI: -23 to 67) in patients with diabetes 
mellitus, lung and heart disease, respectively. 2015/16 
IVE estimates against hospitalised influenza in elderly 
people was moderate against influenza A(H1N1)pdm09 
and B, including among those with diabetes mellitus, 
cancer, lung or heart diseases.
Background
Elderly populations, defined as those aged 65 years 
and above, and, more specifically, elderly people with 
underlying conditions, are at increased risk for hos-
pitalisation due to influenza [1]. Influenza may also 
increase the severity of underlying chronic lung dis-
eases, probably through inflammatory processes [2]. 
Viral pneumonia due to influenza seems to predis-
pose to myocardial infarction, and congestive heart 
failures are more common during influenza seasons 
[3]. Patients with cancer treated with chemotherapy 
[4] and diabetic patients are more vulnerable to influ-
enza. Their impaired immune response [5] could also 
affect host response to vaccination [6,7]. Evidence of 
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the effectiveness of influenza vaccination in prevent-
ing severe clinical outcomes was recently described as 
low or very low among elderly people [8], and among 
patients with cancer [9], diabetes mellitus [10], lung 
diseases [11] [12], or cardiovascular diseases [13].
Despite the Council of the European Union and the 
World Health Organization’s (WHO) recommendations 
to annually vaccinate elderly people [14,15], influenza 
vaccine coverage among elderly people remains below 
the 75% target in most European countries [16].
In this context, post-marketing studies to estimate the 
influenza vaccine effectiveness (IVE) among elderly 
people are needed to inform about vaccination benefits 
for vaccinees, detect subgroups in which the vaccine 
performs less well and identify vaccine types that per-
form best. In 2015, to address this issue, the Integrated 
Monitoring of Vaccines in Europe plus (IMOVE+) con-
sortium initiated a network of hospitals across Europe 
to measure IVE against laboratory-confirmed hospital-
ised influenza among elderly people.
The WHO recommended to include in the 2015/16 tri-
valent influenza vaccine for the northern hemisphere 
an A/California/7/2009 (H1N1)pdm09-like virus, an A/
Switzerland/9715293/2013 (H3N2)-like virus and a B/
Phuket/3073/2013-like virus (Yamagata lineage) [17].
In the 2015/16 influenza season in Europe, influenza 
A(H1N1)pdm09 and influenza B (mainly Victoria lineage) 
viruses predominated [18]. We conducted a multicentre 
hospital-based test-negative design (TND) case–con-
trol study to measure the 2015/16 seasonal IVE against 
hospitalisation with influenza A(H1N1)pdm09 and influ-
enza B among elderly people in Europe, by risk groups 
and for specific vaccine types.
Figure 1
Location of the hospitals participating in the I-MOVE + study, Europe, influenza season 2015/16 (n = 27 hospitals)
I MOVE+: Integrated Monitoring of Vaccines in Europe plus.
Each dot represents one location and there may be more than one hospital in one location.
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Methods
Study sites and design
We set up a European network of 27 hospitals in 11 
countries (Croatia, Finland, France, Hungary, Italy, 
Lithuania, the Netherlands, Poland, Portugal, Romania 
and Spain) (Figure 1), organised in 12 study sites (in 
Spain, Navarre region hospitals had their own coordi-
nation centre). Each study site adapted a generic pro-
tocol to their local setting [19,20]. Monitoring visits 
were organised to ensure the study was done similarly 
across hospitals. We conducted a multicentre TND 
case–control study.
Study period
In each study site, the study period started at least two 
weeks after the beginning of the vaccination campaign 
in the respective countries and lasted from the week 
of the first detection of a laboratory-confirmed case of 
influenza to the week of the last laboratory-confirmed 
case of influenza. We defined different study periods 
for influenza A(H1N1)pdm09 and B.
Study population
Our study population included all community dwelling 
patients aged 65 years and above who had no contrain-
dication for influenza vaccination or previous labora-
tory-confirmed influenza in the season and agreed to 
participate. In the participating services of each hospi-
tal, patients admitted for clinical conditions that could 
be related to influenza were screened for eligibility. 
Study physicians, nurses or collaborating medical staff 
asked patients about onset of symptoms compatible 
with the definition of a severe acute respiratory infec-
tion (SARI) in the previous 7 days.
We defined a SARI case as a hospitalised patient with 
at least one systemic (fever or feverishness, malaise, 
headache, myalgia or deterioration of general or func-
tional condition) and at least one respiratory sign or 
symptom (cough, sore throat or shortness of breath) at 
admission, or within 48 hours after admission.
Data collection
The hospital study teams swabbed patients meeting 
the SARI case definition. Specimens were tested by 
Figure 2
Cases of severe acute respiratory infection with influenza A(H3N2), A(H1N1)pdm09, and B, and negative controls, 
I-MOVE+ study, Europe, influenza season 2015/16 (n = 504 casesa; n = 1,274 controls)
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I-MOVE+: Integrated Monitoring of Vaccines in Europe plus; ISO: International Organisation for Standardisation; SARI: severe acute 
respiratory infection.
a Including two influenza A(H1N1)pdm09 and B co-infections and one influenza A(H3N2) and B co-infection.
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RT-PCR and patients classified as influenza A(H1N1)
pdm09 cases, influenza B cases, other influenza cases 
or controls if their specimens tested negative for any 
influenza virus.
The hospital study teams collected information on 
patients’ age and sex, influenza vaccination status 
including date and brand of the 2015/16 vaccine and 
the status in two previous seasons and underlying con-
ditions listed for clinical risk groups recommended for 
influenza vaccination [21]. The underlying conditions 
included diabetes mellitus, obesity (defined as body 
mass index ≥ 30 kg/m2), cardiovascular conditions 
(such as congenital heart disease, congestive heart 
failure and coronary artery disease), lung diseases 
(such as chronic obstructive pulmonary disease, cystic 
fibrosis, asthma), renal and rheumatologic diseases, 
cancer, stroke, dementia and cirrhosis. Information on 
number of hospitalisations for underlying conditions in 
the previous 12 months, number of general practition-
ers (GP) visits in the previous three months, smoking 
status and functional impairment (based on Barthel 
index score [22]) was also collected.
Information on demographics and underlying condi-
tions were collected from interviews with patients (or 
their relatives) and hospital and/or primary care data-
bases. In study sites with no vaccination register, vac-
cination status was collected through interview with 
patients. For patients vaccinated or unable to provide 
their vaccination status, study sites called patients’ GP 
or pharmacists to retrieve vaccination status, date and 
brand (Table 1).
We defined patients as vaccinated with the 2015/16 
influenza vaccine if they had been vaccinated at least 
14 days before symptoms onset. Otherwise, they were 
considered as unvaccinated.
Data analysis
We computed the IVE as (1 minus the odds ratio (OR) 
of vaccination between cases and controls) x 100. We 
performed a pooled one-stage analysis using the study 
site as a fixed effect and estimated IVE stratified on 
the presence of underlying conditions. All IVE esti-
mates were adjusted for study site, date of SARI symp-
tom onset and age modelled as restricted cubic splines 
with four knots (initial model). To adjust for additional 
potential confounders (sex, each group of underlying 
conditions, hospitalisation in the past year, more than 
one GP visit in the past 3 months, functional impair-
ment, current smoking), we performed a multivariable 
analysis using an onward step by step modelling and 
analysing them as dichotomous variables. Patients 
with missing covariates were excluded from the analy-
ses adjusted for these covariates. We retained in the 
model (full model) all covariates that changed the IVE 
estimate by 10% of more (relative change).
We grouped the vaccine brands in split virion, subu-
nit or adjuvanted vaccines. To compute vaccine type-
specific effectiveness, we restricted our analyses to 
Table 1
Vaccine types used and source of information for vaccination status by study site, I-MOVE + study, Europe, influenza 
season, 2015/16
Study site Number of hospitals Vaccines used
Data sources
Source of information 
for vaccination status
Source of information 
for underlying conditions
Croatia 1 Inactivated subunit I I; H
Finland 2 Inactivated split R; I; GP I; GP; H
France 3 Inactivated subunit; inactivated split I; P I; H
Hungary 2 Adjuvanted I; GP I; H
Italy 3 Inactivated subunit; inactivated split; adjuvanted I; GP I; H
Lithuania 2 Inactivated subunit I; GP I; H
Navarre 3 Inactivated split R I; GP; H
The Netherlands 1 Inactivated subunit; inactivated split I I; H
Poland 3 Unknown I; GP I; H
Portugal 2 Inactivated subunit; inactivated split R; I; GP I; H
Romania 3 Inactivated subunit I; GP I; H
Spain 2 Inactivated subunit; inactivated split R; I; GP I; H
GP: general practitioner/primary care database; H: hospital database/medical charts; I: interview with patient; I-MOVE+: Integrated 
Monitoring of Vaccines in Europe plus; P: pharmacist; R: register
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Table 2
Characteristics of influenza A(H1N1)pdm09 and influenza B hospitalised cases and corresponding test-negative controls 
included in the I-MOVE +  study, Europe, influenza season 2015/16
Influenza A(H1N1)pdm09 Influenza B
Cases 
(n = 355)
Controls 
(n = 976)
Cases 
(n = 110)
Controls 
(n = 1,015)
          n           %           n           %           n           %           n           %
Median age in years (range) 76 (65–95) – 78 (65–101) – 76 (65–94) – 78 (65–101) –
Aged 65–79 years 235/355 66.2 535/976 54.8a 76/110 69.1 566/1,015 55.8a
Sex = male 194/351 55.3 512/975 52.5 57/110 51.8 520/1,014 51.3
2015/16 seasonal influenza 
vaccination 138/355 38.9 543/976 55.6
a 50/110 45.5 588/1,015 57.9a
2014/15 seasonal influenza 
vaccination 136/347 39.2 537/958 56.1
a 53/109 48.6 589/998 59.0a
Type of vaccine 
Not vaccinated 217/353 61.5 433/970 44.6a 60/110 54.5 427/1012 42.2a
Inactivated subunit 77/353 21.8 209/970 21.5 20/110 18.2 207/1012 20.5
Inactivated split virion 59/353 16.7 312/970 32.2 30/110 27.3 332/1012 32.8
Adjuvanted 0/353 0.0 16/970 1.6 0/110 0.0 46/1012 4.5
Underlying conditions 
Diabetes 99/347 28.5 277/954 29.0 31/104 29.8 284/992 28.6
Heart disease 215/351 61.3 590/967 61.0 63/107 58.9 631/1,006 62.7
Lung disease 141/351 40.2 438/965 45.4 46/108 42.6 484/996 48.6
Immunodeficiency 7/343 2.0 34/942 3.6 10/106 9.4 32/986 3.2a
Cancer 93/350 26.6 263/963 27.3 19/105 18.1 280/1,001 28.0a
Nutritional deficiency 16/239 6.7 65/723 9.0 9/84 10.7 51/753 6.8
Renal disease 54/349 15.5 221/960 23.0a 20/106 18.9 236/996 23.7
Dementia or stroke 46/346 13.3 160/956 16.7 17/104 16.3 156/991 15.7
Rheumatologic disease 15/246 6.1 80/737 10.9a 11/87 12.6 83/757 11.0
Obesityb 43/349 12.3 139/951 14.6 5/104 4.8 123/985 12.5a
Any underlying condition 325/350 92.9 908/976 93.0 99/110 90.0 955/1,015 94.1
≥ 2 underlying conditions 244/347 70.3 719/964 74.6 72/108 66.7 752/1,006 74.8
Functional impairmentc 116/347 33.4 347/948 36.6 20/109 18.3 359/988 36.3a
Hospitalisation in past 12 months 152/345 44.1 446/960 46.5 39/108 36.1 475/989 48.0a
Current smoking 79/340 23.2 183/901 20.3 36/102 35.3 210/927 22.7a
Study sites 
Croatia 16/355 4.5 15/976 1.5 5/110 4.5 3/1,015 0.3
Finland 18/355 5.1 57/976 5.8 3/110 2.7 35/1,015 3.4
France 11/355 3.1 124/976 12.7 26/110 23.6 124/1,015 12.2
Hungary 0/355 0.0 0/976 0.0 1/110 0.9 5/1,015 0.5
Italy 3/355 0.8 102/976 10.5 10/110 9.1 249/1,015 24.5
Lithuania 17/355 4.8 41/976 4.2 3/110 2.7 31/1,015 3.1
Navarra 87/355 24.5 240/976 24.6 27/110 24.5 230/1,015 22.7
The Netherlands 5/355 1.4 12/976 1.2 3/110 2.7 6/1,015 0.6
Poland 17/355 4.8) 14/976 1.4 6/110 5.5 9/1,015 0.9
Portugal 14/355 3.9 35/976 3.6 1/110 0.9 1/1,015 0.1
Romania 58/355 16.3 101/976 10.3 2/110 1.8 70/1,015 6.9
Spain 109/355 30.7 235/976 24.1 23/110 20.9 252/1,015 24.8
Potential for misclassification 
Antivirals before swabbing 36/353 10.2 32/972 3.3a 7/107 7.5 27/1,012 2.7a
Swabbing within  3 days of onset 216/355 60.8 518/976 53.1a 54/110 49.1 585/1,015 57.6
I MOVE+: Integrated Monitoring of Vaccines in Europe plus.
a Indicates a significant difference (p value < 0.05) between cases and controls.
b Defined as body-mass index ≥ 30 kg/m2.
c Defined as Barthel score < 100 [22].
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countries with at least one patient vaccinated with a 
specific type.
We also computed a pooled IVE with a two-stage model, 
adjusting study site-specific IVE for study site-specific 
confounders (same as listed above) when sample size 
allowed. We quantified the heterogeneity between site 
estimates using the I-square [23].
To minimise the inclusion of false influenza-negatives 
in the control group, we carried out sensitivity analyses 
by restricting population to (i) patients swabbed up to 
three days after symptom onset and (ii) patients not 
treated with antivirals until the day before swabbing.
Results
A total of 2,077 patients meeting the inclusion criteria 
were recruited in the study. We excluded 472 controls 
(23%) recruited outside of the study period and 65 
patients (4%) with missing information on vaccination 
status. We included 1,274 controls and 528 cases, of 
which 353 (67%) were influenza A(H1N1)pdm09 posi-
tive, 105 (20%) were influenza B-positive, 41 (8%) were 
influenza A(H3N2)-positive, 24 (5%) were influenza A 
(non-subtyped)-positive, two (<1%) were co-infected 
by influenza A(H1N1)pdm09 and B, one (<1%) was co-
infected by influenza A(H3N2) and B and two (<1%) 
were co-infected by influenza A (non-subtyped) and B. 
Of the 52 cases of influenza B with a known lineage, 47 
Table 3
Pooled adjusted seasonal influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09 overall among 
elderly people, by risk groups and vaccine type, I-MOVE +  study, Europe, influenza season, 2015/16
Analyses Model used for adjustmenta
Vaccinated 
/cases
Vaccinated 
/controls Adjusted IVE    95% CI   
Overall 
Initial 138/355 543/976 42.4 22.0 to 57.4
Full 131/336 509/923 39.4 16.6 to 55.9
By risk groups 
At least one underlying condition
Initial
130/317 499/892
35.7 11.4 to 53.3
Initial plus severity 35.6 11.2 to 53.3
Diabetes mellitus
No Initial 98/242 370/674 33.9 4.6 to 54.2
Yes
Initial
33/96 150/266
58.5 22.8 to 77.7
Initial plus severity 58.5 22.7 to 77.8
Heart disease
No Initial 54/131 207/372 37.3 -1.2 to 61.1
Yes
Initial
80/211 321/581
38.4 6.5 to 59.5
Initial plus severity 39.0 7.3 to 59.9
Lung disease
No Initial 61/203 250/515 39.7 8.0 to 60.4
Yes
Initial
72/139 276/434
42.4 7.2 to 64.3
Initial plus severity 42.8 7.8 to 64.5
Cancer
No Initial 93/252 375/691 35.7 6.7 to 55.7
Yes
Initial
41/90 150/256
47.7 4.8 to 71.3
Initial plus severity 47.8 4.8 to 71.4
Vaccine type 
Inactivated subunit Initial 77/224 209/538 28.1 -8.6 to 52.4
Inactivated split virion Initial 59/178 312/588 54.7 30.7 to 70.4
Sensitivity analyses 
Two-stage model two-stageb 132/329 527/932 49.0 13.5 to 70.0
Restricted to patients swabbed within 
3 days Initial 85/216 313/518 49.1 23.8 to 66.0
Restricted to patients not receiving 
antivirals before swabbing Initial 126/317 531/940 42.2 20.8 to 57.8
CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.
a Initial: one-stage model adjusted for study site, date of symptom onset and age (modelled as restricted cubic splines). Full: one-stage model 
adjusted for study site, date of symptom onset, age (modelled as restricted cubic splines), lung, heart, renal disease, diabetes mellitus, 
cancer, obesity (body-mass index ≥ 30 kg/m2) and hospitalisation for underlying conditions in past year. Severity: hospitalisations for 
underlying conditions in the previous year.
b Poland and Hungary were excluded because there were no vaccinated controls in Poland and no cases in Hungary.
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(90%) were Victoria and 5 (10%) were Yamagata. The 
42 cases positive for influenza A(H3N2) did not allow 
us to compute IVE against this subtype.
The maximum number of influenza A(H1N1)pdm09 
cases were recruited in weeks 5 to 8 of 2016 and the 
maximum number of influenza B and A(H3N2) cases in 
week 10 (Figure 2).
Overall, 216/528 cases (41%) and 694/1,274 controls 
(54%) had received trivalent inactivated vaccines. 
Among those vaccinated, 51 (6%) received adjuvanted 
vaccines, 338 (37%) inactivated subunit vaccines,513 
(56%) inactivated split virion vaccines and the informa-
tion on vaccine type was missing for 8 (1%) vaccinated 
patients. Age and time adjusted IVE against any influ-
enza was 39% (95 % confidence interval (CI): 22 to 53).
Vaccine effectiveness against hospitalised 
influenza A(H1N1)pdm09
We included in this analysis 355 cases of influenza 
A(H1N1)pdm09, of whom 138 (39%) were vaccinated, 
and 976 controls, of whom 543 (56%) vaccinated. The 
median age of A(H1N1)pdm09 cases and controls was 
76 (Interquartile range (IQR) = 12 years) and 78 (IQR 
= 12 years) years respectively (p = 0.001). The propor-
tion of patients with underlying conditions was similar 
among cases and controls except for renal (16% among 
cases vs 23% among controls, p = 0.003) and rheuma-
tologic diseases (6% among cases vs 11% among con-
trols, p = 0.033). Ten percent of A(H1N1)pdm09 cases 
and 3% of controls had received antivirals before 
swabbing (p < 0.001) and 61% of cases vs 53% of con-
trols were swabbed within 3 days after symptoms onset 
(p = 0.013) (Table 2).
One-stage pooled IVE against A(H1N1)pdm09 adjusted 
for onset time and age was 42% (95%  CI: 22 to 57) 
and 39% (95% CI: 17 to 56) when further adjusted for 
a range of underlying conditions and hospitalisation in 
the previous year (Table 3). IVE against A(H1N1)pdm09 
was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% 
(95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients 
with diabetes mellitus (n = 362), cancer (n = 346), lung 
(n = 573) and heart disease (n = 792), respectively 
(Table 3).
IVE against A(H1N1)pdm09 was 28% (95%  CI: −9 to 
52) for inactivated subunit vaccines (n = 762) and 55% 
(95%  CI: 31 to 70) for inactivated split virion vaccines 
(n = 716).
Study site specific IVE ranged between −152% (95% CI: 
−3,081 to 80) in Italy (n = 105) and 95% (95%  CI: 7 to 
100) in the Netherlands (n = 17) (Table 4). The statisti-
cal heterogeneity between study site specific IVE esti-
mates was moderate (I2 = 36%). The two-stage pooled 
analysis (n = 1,261) included Croatia, Finland, France, 
Italy, Lithuania, Navarre, the Netherlands, Portugal, 
Romania and Spain. IVE was 49% (95%  CI: 14 to 70). 
In sensitivity analyses, IVE against influenza A(H1N1)
pdm09 was 42% (95%  CI: 21 to 58) when restricting 
to patients not having received antiviral treatment 
(n = 1,257) and 49% (95% CI: 24 to 66) among patients 
Table 4
Study site specific and two-stagea pooled seasonal vaccine effectiveness against hospitalised influenza A(H1N1)pdm09 
among elderly people, I- MOVE + study, Europe, influenza season 2015/16 (n = 1,261)
Study site Inclusion period Variables used for adjustmentb
Vaccinated 
/cases
Vaccinated 
/controls
Adjusted 
IVE          95% CI          I-square
Croatia 2016w5–2016w13 Date 4/16 1/15 -122.0 −4,314.5 to 88.8 – 
Finland 2015w50–2016w7 Date 5/18 38/57 85.0 43.7 to 96.0 –
France 2016w4–2016w14 Date 3/11 84/124 83.7 32.2 to 96.1 –
Italy 2016w5–2016w11 Date 2/3 47/102 -152.2 −3,081.1 to 80.0 –
Lithuania 2016w2–2016w10 Date 1/17 7/41 66.8 −210.4 to 96.4 –
Navarra 2015w46–2016w13 Date 46/87 169/240 45.9 5.3 to 69.1 –
The 
Netherlands 2015w50–2016w7 Date 1/5 10/12 94.8 6.9 to 99.7 –
Portugal 2015w51–2016w8 Date, cancer, obesity 3/14 14/35 11.9 −372.7 to 83.6 –
Romania 2016w3–2016w14 Date, cancer, renal disease 4/58 6/100 -22.6 −490.3 to 74.6 –
Spain 2016w1–2016w14 Date, age, heart disease, dependency 63/100 151/206 22.5 −39.6 to 56.9 –
two-stage 
pooled                 – – – – 49.0 13.5 to 70.0 36.2%
CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness; w: week 
(International Organisation for Standardisation (ISO) week).
a Poland and Hungary were excluded from the two-stage analyses because there were no vaccinated controls in Poland and no cases in 
Hungary.
b Date of symptom onset and age modelled as restricted cubic spline with four knots.
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swabbed within 3 days of symptoms onset (n = 734) 
(Table 3).
Vaccine effectiveness against hospitalised 
influenza B
We included in this analysis 110 cases of influenza 
B, of whom 50 (46%) were vaccinated and 1,015 con-
trols, of whom 588 (58%) vaccinated. The median age 
of cases and controls were 76 (IQR: 12 years) and 78 
years (IQR: 12 years) respectively (p = 0.056). A lower 
proportion of cases than controls had cancer (18% vs 
28%, p = 0.037), a functional impairment (18% vs 36%, 
p < 0.001), and had been hospitalised in the previous 12 
months (36% vs 48%, p = 0.02). The proportion of cur-
rent smokers was higher among influenza B cases than 
among controls (35% vs 23%, p = 0.007) (Table 2).
One stage pooled IVE against influenza B adjusted for 
symptom onset time and age was 52% (95% CI: 24 to 
70) and 47% (95% CI: 13 to 68) when further adjusted 
for a range of underlying conditions and hospitalisation 
in the previous year (Table 5). IVE was 62% (95% CI: 5 
to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: −23 
to 67) in patients with diabetes mellitus (n = 302), lung 
(n = 520) and heart disease (n = 675), respectively.
IVE against influenza B was 49% (95%  CI: 14 to 70) 
for inactivated subunit vaccines (n = 603) and 54% 
(95%  CI: 19 to 74) for inactivated split virion vaccines 
(n = 726).
Study site specific IVE ranged between 18% (95%  CI: 
−106 to 67) in Finland (n = 38) and 76% (95%  CI: −24 
to 95) in Italy (n = 259) (Table 6). There was no statis-
tical heterogeneity between study site specific IVE 
Table 5
Pooled adjusted seasonal vaccine effectiveness against hospitalised influenza B among elderly people overall and by risk 
groups, I-MOVE + study, Europe, influenza season 2015/16
Model used for 
adjustmenta
Vaccinated 
/cases
Vaccinated 
/controls Adjusted IVE       95% CI      
Overall 
Overall Initial 50/110 588/1,015 51.8 23.7 to 69.5
Overall Full 46/101 544/948 47.0 13.1 to 67.7
By risk groups 
At least one underlying condition
Initial
47/97 536/929
50.2 18.7 to 69.4
Initial plus severity 49.4 17.5 to 69.0
Diabetes mellitus
No Initial 33/72 404/696 40.9 −7.1 to 67.4
Yes
Initial
13/30 152/272
62.1 5.8 to 84.7
Initial plus severity 62.0 5.3 to 84.8
Heart disease
No Initial 16/44 211/368 66.5 27.6 to 84.5
Yes
Initial
32/61 354/614
36.3 −22.2 to 66.8
Initial plus severity 36.1 −22.9 to 66.7
Lung disease
No Initial 27/61 258/502 32.8 −28.6 to 64.8
Yes
Initial
22/45 305/475
60.5 19.2 to 80.6
Initial plus severity 59.9 18.2 to 80.4
Vaccine type 
Inactivated subunit Initial 20/61 207/542 49.0 13.5 to 70.0
Inactivated split virion Initial 30/74 332/652 54.1 18.9 to 74.0
Sensitivity analyses 
two-stage model two-stageb 48/86 551/858 47.0 11.9 to 68.2
Restricted to patients swabbed 
within 3 days Initial 31/54 358/585 25.0 −50.5 to 62.6
Restricted to patients not receiving 
antivirals before swabbing Initial 46/99 577/985 52.3 22.8 to 70.5
CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.
a Initial: one-stage model adjusted for study site, date of onset and age (modelled as restricted cubic splines). Full: one-stage model adjusted 
for study site, date of symptom onset, age (modelled as restricted cubic splines), lung, heart, renal disease, diabetes mellitus, cancer, 
obesity and hospitalisation in the previous year Severity: hospitalisations for underlying conditions in the previous year.
b Croatia, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal and Romania were excluded from the two-stage analyses because there 
were no vaccinated controls and/or cases, respectively.
9www.eurosurveillance.org
estimates (I2 = 0%). The two-stage pooled analysis 
(n = 944) included Finland, France, Italy, Navarre and 
Spain. IVE was 47% (95%  CI: 12 to 68). In sensitivity 
analyses, IVE against influenza B was 52% (95% CI: 23 
to 71) when restricting to patients not having received 
antiviral treatment (n = 1,084) and 25% (95%CI: −51 to 
63) among patients swabbed within 3 days of symp-
toms onset (n = 639).
Discussion
Our results suggest that the seasonal IVE against hos-
pitalised influenza among elderly people was moder-
ate during the 2015/16 influenza season in Europe for 
influenza: 39% overall, 42% against influenza A(H1N1)
pdm09 and 52% against influenza B . These esti-
mates did not vary between categories of underlying 
conditions.
Data from European virological surveillance reported 
that most of the characterised influenza A(H1N1)pdm09 
viruses belonged to the emerging subclade 6B.1, 
defined by haemagglutinin amino acid substitutions 
S162N and I216T [18]. Despite these genetic evolutions, 
A(H1N1)pdm09 viruses were considered antigenically 
similar to the northern hemisphere vaccine component 
A/California/7/2009. IVE estimates against hospital-
ised A(H1N1)pdm09 was consistent with the results we 
reported in 2012/13 and 2013/14 among hospitalised 
elderly people [24,25].
In 2015/16, the circulating influenza B Victoria lineage 
was distinct from the Yamagata vaccine component 
[26] and there was no quadrivalent vaccine used in our 
study population. IVE against influenza B was close to 
what we reported, using the same generic protocol, in 
2012/13 (66% in the 65–79 year-olds and 44% in the 
80 year-olds and older) in a season with co-circulation 
of B Victoria and Yamagata lineages and a Yamagata 
vaccine component [24,27]. These results suggest 
some cross-lineage protection and they are in line with 
previously reported data in GP-based studies [28,29] 
and a meta-analysis of eight randomised controlled tri-
als with mismatched B viruses resulting in a VE of 52% 
(95%  CI: 19 to 72) among healthy adults [30]. Further 
studies are needed to increase the understanding of 
mechanisms of cross-lineage protection for influenza 
B and better guide policy makers in terms of recom-
mendations for using trivalent or tetravalent seasonal 
vaccines.
We observed higher point estimates of IVE for the inac-
tivated split virion vaccines compared with inactivated 
subunit vaccines, although the 95%  CIs of the point 
estimates were widely overlapping. The completeness 
of data on vaccine type was high (1% of missing vac-
cine type among those vaccinated), thus these results, 
concurring with published data [31-33], could be due 
to differences in T-cell responses conferred by the 
two vaccine types [34]. However, they should be inter-
preted with caution as they may be due to random vari-
ation. Further evidence, and pooling of several years of 
data would be required to obtain precise vaccine type 
specific effectiveness. Higher adjuvant vaccine cov-
erage would be needed to compute adjuvant vaccine 
specific IVE. This would be useful information to adapt 
influenza vaccination strategies among elderly people.
Recent reviews underlined the need for further evi-
dence of seasonal IVE against laboratory-confirmed 
influenza in elderly people and patients with underly-
ing conditions [8-13]. We were able to collect high qual-
ity data from 1,802 elderly patients hospitalised with 
SARI, making our study one of the largest hospital-
based studies on IVE. The large number of participants, 
Table 6
Study site-specific and two-stagea pooled seasonal vaccine effectiveness against hospitalised influenza B among elderly 
people, I- MOVE + study, Europe, influenza season 2015/16
Study site       Inclusion period       Variables used for adjustmentb
Vaccinated 
/cases
Vaccinated 
/controls Adjusted IVE         95% CI         I-square
Finland 2016w8–2016w15 Date 2/3 22/35 23.3 -1,785.9 to 96.9 –
France 2016w4–2016w14 Date, age, functional impairment 17/26 87/120 18.1 -105.6 to 67.4 –
Italy 2016w1–2016w12 Date 2/10 121/249 75.5 -23.7 to 95.1 –
Navarre 2015w53–2016w17 Date 17/27 165/230 59.4 -2.5 to 83.9 –
Spain 2016w2–2016w16 Date, lung disease, dependency 11/20 159/220 44.3 -48.9 to 79.1 –
two-stage 
pooled 
(n = 944)
– – – – 47.0 11.9 to 68.2 0.0%
CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness; w: week 
(International Organisation for Standardisation (ISO) week).
a Croatia, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal and Romania were excluded from the two-stage analyses because there 
were no vaccinated controls and/or cases.
b Date of onset and age modelled as restricted cubic spline with four knots.
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and a vaccine coverage close to 50%, enabled us to 
compute IVE against type/subtype-specific influenza 
among patients with specific underlying conditions. 
Our results suggest that, in 2015/16, the seasonal 
influenza vaccine provided protection against hospi-
talised influenza A(H1N1)pdm09 and B in the elderly 
with diabetes mellitus, heart and lung disease. We 
were unable to refine the underlying conditions cat-
egories further. To better guide vaccine recommenda-
tions, IVE among patients receiving specific treatment 
(e.g. statins [35,36], chemotherapy [9,37]) or with more 
specific conditions (e.g. asthma, chronic obstructive 
pulmonary disease) would be needed. A larger sample 
size would be required for such studies.
We collected information related to access to care, 
health conditions and smoking status. Recruited cases 
and controls were similar. We adjusted our estimates 
for study site, onset week and age. Further adjust-
ment for potential confounders (underlying lung, heart, 
renal disease, diabetes mellitus, cancer, obesity and 
hospitalisations in the past year) did not change the 
estimates. However, as in any observational study, we 
cannot exclude unmeasured confounding leading to 
over- or under-estimation of the IVE.
The contribution to the pooled dataset was different 
between study sites. The two Spanish sites recruited 
44% of the patients. The viruses circulating and vac-
cines used in Spain were similar to the other countries. 
Consequently we do not expect the over-representation 
of Spanish sites to have biased our overall estimates. 
Variations in the number of recruited individuals may 
be explained by differences in local influenza activ-
ity or number and size of participating hospitals/
services. We believe that access to hospitalisation in 
case of severe influenza is similar across participating 
European countries. A common generic protocol and 
the monitoring of its implementation through on-site 
visits contributed to ensuring comparability of patients 
recruited and data collected across study sites. We 
measured low statistical heterogeneity based on 
I-square values. However, small number of estimates 
and large study-specific CIs may hinder adequate quan-
titative assessment of heterogeneity between studies 
[38]. True differences between study site specific IVE 
could be related to different vaccines used during this 
season or different immunological profiles of recruited 
patients including their past vaccination histories [39]. 
Larger study site-specific sample sizes are required to 
ensure that the differences in IVE across study sites are 
not due to chance. Currently, multicentre studies are 
necessary to obtain precise IVE estimates.
A recent publication by Foppa et al. suggested that 
measuring IVE against laboratory-confirmed influenza 
SARI hospitalisation using the TND was subject to 
biases if the test-negative controls were hospitalised 
because of an exacerbation of underlying lung disease 
unrelated to a respiratory infection [40]. In our study, 
cases and controls had similar prevalence of underlying 
lung disease. Underlying lung disease did not appear 
to confound IVE estimates, even when combined with a 
proxy of its severity (hospitalisation because of under-
lying conditions in the past 12 months). Cohort and 
TND-based IVE estimates against laboratory-confirmed 
hospitalised influenza in Navarre repeatedly showed 
similar estimates, reassuring on the appropriateness 
of TND at hospital level [41].
Several studies suggest that past influenza vaccina-
tions may decrease or enhance current vaccine effec-
tiveness depending on previous and current vaccine 
and circulating strains as well as past exposure to the 
virus [24,32,42-44]. A large proportion of our vacci-
nated population had been vaccinated in the previous 
season(s) but the very small number of patients with 
varying repeated vaccination status over the years did 
not allow us to measure the effect of previous vacci-
nations. To understand the effect of repeated vaccina-
tions on IVE, large cohorts of individuals with different 
vaccination patterns and symptomatic (and asympto-
matic) influenza infection status over the years would 
be needed.
Conclusion
Our multicentre test-negative case–control study esti-
mated that in 2015/16 the seasonal influenza vacci-
nation prevented approximately half of the cases of 
hospitalisation with laboratory-confirmed influenza 
among vaccinated elderly people. Our results suggest 
that vaccination provided similar protection to elderly 
patients with underlying diabetes mellitus, cancer, 
lung and heart diseases. Because vaccination remains 
the most effective preventive measure against severe 
influenza among elderly people, increasing the vaccine 
coverage in this group should be a priority. This pilot 
season of the hospital-based I-MOVE + project proved 
that obtaining precise estimates of IVE against a severe 
influenza outcome among elderly people was feasible. 
Enlarging our network and its sample size will ena-
ble us to better guide vaccination strategies against 
severe influenza cases by comparing the performance 
of different vaccine types and identifying risk groups 
for poor response to vaccination.
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